文献速递神经MR

半剂量高弛豫率对比剂增强T2 FLAIR成像脑转移瘤的效用

Utility of Contrast-Enhanced T2 FLAIR for Imaging Brain Metastases Using a Half-dose High-Relaxivity Contrast Agent.
PubMed 文献 · AJNR Am J Neuroradiol · 2020-12-24

前瞻性研究探讨半剂量钆贝葡胺增强T2 FLAIR对脑转移瘤的成像价值:体外实验显示T2 FLAIR最大信号强度所需对比剂浓度仅为T1WI的1/8至1/2;46例肺癌患者行半剂量增强T2 FLAIR连续3期及半剂量自旋回波T1WI,追加0.05 mmol/kg后行3D脑容积成像,结果显示小病灶或环形强化转移瘤在延迟增强T2 FLAIR上显示更佳。

要点

  • 半剂量高弛豫率对比剂增强T2 FLAIR连续3期转移瘤平均对比率范围为63.64%至83.05%。
  • 环形强化≥5 mm组对比率增加百分比高于实性强化≥5 mm组(P=.001)及直径<5 mm组(P<.001)。
  • 直径<5 mm组增强T2 FLAIR强化程度高于3D脑容积成像(P<.001),实性强化≥5 mm组则低于后者(P<.001)。

关键影像表现/征象

  • 体外T2 FLAIR最大信号强度出现在T1WI最大信号强度所需对比剂浓度的1/8至1/2处。
  • 体内增强T2 FLAIR连续3期转移瘤平均对比率范围为63.64%至83.05%。
  • 增强T2 FLAIR对比率增加百分比:实性强化≥5 mm组(A组)低于环形强化≥5 mm组(B组)(P=.001),A组低于直径<5 mm组(C组)(P<.001)。
  • 增强T2 FLAIR强化程度:A组低于3D脑容积成像(P<.001),C组高于3D脑容积成像(P<.001)。

诊断标准与关键数值

  • 脑转移瘤分类:A组为实性强化且≥5 mm,B组为环形强化且≥5 mm,C组为病灶直径<5 mm。
  • 对比率增加百分比比较:PIA<PIB(P=.001),PIA<PIC(P<.001)。
  • 增强T2 FLAIR与3D脑容积成像强化程度比较:A组增强T2 FLAIR低于3D脑容积成像(P<.001),C组增强T2 FLAIR高于3D脑容积成像(P<.001)。

临床应用与阅片要点

  • 采用半剂量高弛豫率对比剂时,延迟增强T2 FLAIR有助于更好显示小病灶或环形强化脑转移瘤。
  • 阅片时需注意:实性强化≥5 mm病灶在增强T2 FLAIR上的强化程度低于3D脑容积成像。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Efficient detection of metastases is important for patient' treatment. This prospective study was to explore the clinical value of contrast-enhanced T2 FLAIR in imaging brain metastases using half-dose gadobenate dimeglumine.

MATERIALS AND METHODS: In vitro signal intensity of various gadolinium concentrations was explored by spin-echo T1-weighted imaging and T2 FLAIR. Then, 46 patients with lung cancer underwent nonenhanced T2 FLAIR before administration of half-dose gadobenate dimeglumine and 3 consecutive contrast-enhanced T2 FLAIR sequences followed by 1 spin-echo T1WI after administration of half-dose gadobenate dimeglumine. After an additional dose of 0.05 mmol/kg, 3D brain volume imaging was performed. All brain metastases were classified as follows: solid-enhancing, ≥ 5 mm (group A); ring-enhancing, ≥ 5 mm (group B); and lesion diameter of <5 mm (group C). The contrast ratio of the lesions on 3 consecutive phases of contrast-enhanced T2 FLAIR was measured, and the percentage increase of contrast-enhanced T2 FLAIR among the 3 groups was compared.

RESULTS: In vitro, the maximal signal intensity was achieved in T2 FLAIR at one-eighth to one-half of the contrast concentration needed for maximal signal intensity in T1WI. In vivo, the mean contrast ratio values of metastases on contrast-enhanced T2 FLAIR for the 3 consecutive phases ranged from 63.64% to 83.05%. The percentage increase (PI) values of contrast-enhanced T2 FLAIR were as follows: PIA < PIB (P = .001) and PIA < PIC (P < .001). The degree of enhancement of brain metastases on contrast-enhanced T2 FLAIR was lower than on 3D brain volume imaging (P < .001) in group A, and higher than on 3D brain volume imaging (P < .001) in group C.

CONCLUSIONS: Small or ring-enhancing metastases can be better visualized on delayed contrast-enhanced T2 FLAIR using a half-dose high-relaxivity contrast agent.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Jin T, Ge M, Huang R, et al. Utility of Contrast-Enhanced T2 FLAIR for Imaging Brain Metastases Using a Half-dose High-Relaxivity Contrast Agent. AJNR Am J Neuroradiol. 2020. PMID: 33361381. doi:10.3174/ajnr.A6931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。